Pharmacological treatment strategies for dry eye disease (DED) have evolved significantly, incorporating a range of therapeutic interventions targeting underlying inflammation and tear production deficits. Nonsteroidal anti-inflammatory drugs and tumor necrosis factor-alpha inhibitors, such as adalimumab, are increasingly used to manage severe cases of DED, showing efficacy in reducing symptoms and improving ocular surface integrity.
Methods:
This review will comprehensively evaluate the use of platelet-rich plasma (PRP) in the treatment of dry eye (DE) and its possible mechanism of action.
Results:
Novel immunotherapy targets and gene therapy methodologies are developing, showcasing significant progress in the inhibition of reactive aldehyde species and the application of CRISPR-Cas9 technology to modulate immune responses and promote tissue repair. PRP, abundant in growth factors, is increasingly acknowledged as an efficacious therapy, especially for persistent epithelial defects and severe DED. PRP has demonstrated advantages in expediting wound healing and tissue regeneration owing to its powerful biological constituents, such as transforming growth factor-β, vascular endothelial growth factor, and platelet-derived growth factor.
Conclusion:
Recent research underscores the variations in preparation techniques for PRP, with formulations like E-PRP (eye-specific PRP) used for ocular surface therapies. Moreover, the increasing application of autologous serum and plasma rich in growth factors for the treatment of DED is substantiated by data indicating their capacity to enhance corneal epithelialization and mitigate DE symptoms. This review highlights the increasing significance of new therapeutic modalities, such as PRP, as essential for controlling DED, offering effective alternatives with improved clinical results.
PhadatareSP, MominM, NighojkarP, et al.A comprehensive review on dry eye disease: Diagnosis, medical management, recent developments, and future challenges. Advances in Pharmaceutics, 2015; 2015(1):1–12.
2.
PerezVL, ChenW, CraigJP, et al.TFOS DEWS III Editorial. Am J Ophthalmol, 2025; 278:166–167; doi: 10.1016/j.ajo.2025.05.038
3.
Suárez-CortésT, Merino-IndaN, Benitez-del-CastilloJM. Tear and ocular surface disease biomarkers: A diagnostic and clinical perspective for ocular allergies and dry eye disease. Exp Eye Res, 2022; 221:109121.
CelebiARC, UlusoyC, MirzaGE. The efficacy of autologous serum eye drops for severe dry eye syndrome: A randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol, 2014; 252(4):619–626.
6.
JirsovaK, BrejchovaK, KrabcovaI, et al.The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment. Curr Eye Res, 2014; 39(1):21–30.
7.
LempMA, FoulksGN. The definition and classification of dry eye disease. Ocul Surf, 2007; 5(2):75–92.
8.
AnituaE, SanchezM, Merayo-LlovesJ, et al.Plasma Rich in Growth Factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-β1–induced myodifferentiation. Invest Ophthalmol Vis Sci, 2011; 52(9):6066–6073.
9.
AnituaE, MuruzabalF, AlcaldeI, et al.Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery. Exp Eye Res, 2013; 115:153–161.
10.
AnituaE, MuruzabalF, De la FuenteM, et al.Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res, 2014; 119:27–34.
11.
AnituaE, MuruzabalF, PinoA, et al.Biological stability of plasma rich in growth factors eye drops after storage of 3 months. Cornea, 2013; 32(10):1380–1386.
12.
MarxRE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent, 2001; 10(4):225–228.
13.
HojjatA, MansourRN, EnderamiSE, et al.The differentiation and generation of glucose-sensitive beta like-cells from menstrual blood-derived stem cells using an optimized differentiation medium with platelet-rich plasma (PRP). Acta Histochem, 2023; 125(3):152025; doi: 10.1016/j.acthis.2023.152025
14.
FilardoG, Di MatteoB, KonE, et al.Platelet-rich plasma in tendon-related disorders: Results and indications. Knee Surg Sports Traumatol Arthrosc, 2018; 26(7):1984–1999.
15.
BelkJW, KraeutlerMJ, HouckDA, et al.Platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Am J Sports Med, 2021; 49(1):249–260.
16.
XuanZ, YuW, DouY, et al.Efficacy of platelet-rich plasma for low back pain: A systematic review and meta-analysis. J Neurol Surg A Cent Eur Neurosurg, 2020; 81(6):529–534.
17.
BoswellSG, ColeBJ, SundmanEA, et al.Platelet-rich plasma: A milieu of bioactive factors. Arthroscopy, 2012; 28(3):429–439.
18.
FosterTE, PuskasBL, MandelbaumBR, et al.Platelet-rich plasma: From basic science to clinical applications. Am J Sports Med, 2009; 37(11):2259–2272.
LempM, FoulksG. The epidemiology of dry eye disease: Report of the epidemiology subcommittee of the international dry eye workshop (2007). Ocul Surf, 2007; 5(2):93–107.
21.
PouyehB, ViteriE, FeuerW, et al.Impact of ocular surface symptoms on quality of life in a United States veterans affairs population. Am J Ophthalmol, 2012; 153(6):1061–1066.e3.
22.
CraigJP, NicholsKK, AkpekEK, et al.TFOS DEWS II definition and classification report. Ocul Surf, 2017; 15(3):276–283.
23.
SternME, SchaumburgCS, PflugfelderSC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol, 2013; 32(1):19–41.
24.
GodinMR, GuptaPK. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: Design, development, and place in therapy. Clin Ophthalmol, 2017; 11:951–957.
25.
LempMA, CrewsLA, BronAJ, et al.Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: A retrospective study. Cornea, 2012; 31(5):472–478.
26.
McCannP, KruochZ, LopezS, et al.Interventions for dry eye: An overview of systematic reviews. JAMA Ophthalmol, 2024; 142(1):58–74.
27.
BegleyCG, ChalmersRL, AbetzL, et al.The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci, 2003; 44(11):4753–4761.
28.
SjögrenH. A New Conception of Keratoconjunctivitis Sicca. Australasian medical Publishing Company Limited; 1943.
29.
Abdel-KhalekL, WilliamsonJ, LeeW. Morphological changes in the human conjunctival epithelium. II. In keratoconjunctivitis sicca. Br J Ophthalmol, 1978; 62(11):800–806.
30.
GilbardJ, RossiSR, GrayKL. A new rabbit model for keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci, 1987; 28(2):225–228.
31.
LuoL, LiD-Q, DoshiA, et al.Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci, 2004; 45(12):4293–4301.
32.
GilbardJ, RossiS, GrayK, et al.Tear film osmolarity and ocular surface disease in two rabbit models for keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci, 1988; 29(3):374–378.
33.
YangL, LiJ, ZhouB, et al.An injectable copolymer for in situ lubrication effectively relieves dry eye disease. ACS Materials Lett, 2025; 7(3):884–890.
34.
MohamedZ, AlrasheedS, AbduM, et al.Dry eye disease prevalence and associated risk factors among the middle east population: A systematic review and meta-analysis. Cureus, 2024; 16(9):e70522.
35.
MohamedHB, Abd El-HamidBN, FathallaD, et al.Current trends in pharmaceutical treatment of dry eye disease: A review. Eur J Pharm Sci, 2022; 175:106206.
36.
ChuL, WangC, ZhouH. Inflammation mechanism and anti-inflammatory therapy of dry eye. Front Med (Lausanne), 2024; 11:1307682.
37.
BlumenkranzMS, OhanaE, ShaikhS, et al.Adjuvant Methods in Macular Hole Surgery: Intraoperative Plasma-Thrombin Mixture and Postoperative Fluid-Gas Exchange. SLACK Incorporated: Thorofare, NJ; 2001.
38.
AnituaE, AguirreJJ, AlgortaJ, et al.Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater, 2008; 84(2):415–421.
39.
LiuZ, XieH, LiL, et al.Single-cell landscape reveals the epithelial cell-centric pro-inflammatory immune microenvironment in dry eye development. Mucosal Immunol, 2024; 17(3):491–507.
40.
BuJ, LiuY, ZhangR, et al.Potential new target for dry eye disease—oxidative stress. Antioxidants (Basel), 2024; 13(4):422.
41.
ShuDY, ChaudharyS, ChoK-S, et al.Role of oxidative stress in ocular diseases: A balancing act. Metabolites, 2023; 13(2):187.
42.
WangL, LiX, MenX, et al.Research progress on antioxidants and protein aggregation inhibitors in cataract prevention and therapy. Mol Med Rep, 2025; 31(1):22.
43.
OrtizG, BlancoT, SinghRB, et al.IL-6 induces Treg dysfunction in desiccating stress-induced dry eye disease. Exp Eye Res, 2024; 246:110006.
44.
LiM, GongL, SunX, et al.Anxiety and depression in patients with dry eye syndrome. Curr Eye Res, 2011; 36(1):1–7.
45.
LanaJF, MacedoA, IngraoILG, et al.Leukocyte-rich PRP for knee osteoarthritis: Current concepts. J Clin Orthop Trauma, 2019; 10(Suppl 1):S179–S182.
46.
AnituaE. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. International Journal of Oral and Maxillofacial Implants, 1999; 14(4):529–535.
ForouzanfarF, Pourbagher-ShahriAM, ForoozanfarE, et al.Pharmacological effects of nigella sativa in ocular diseases. Rev Bras Farmacogn, 2025; 35(2):325–332.
49.
VargasJCB, CórdobaCJM, RoblesLAR. Effect of the use of biological therapy on dry eye parameters in patients with Sjögren’s syndrome. The Pan-American Journal of Ophthalmology, 2024; 6(3):102.
50.
HuangD, LiZ. Multidimensional immunotherapy for dry eye disease: Current status and future directions. Front Ophthalmol (Lausanne), 2024; 4:1449283.
51.
KatzmanLR, JengBH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol, 2014; 28(3):168–172.
52.
ZimmermannR, JakubietzR, JakubietzM, et al.Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion, 2001; 41(10):1217–1224.
53.
KimKM, ShinY-T, KimHK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol, 2012; 56(6):544–550.
54.
HartwigD, HarloffS, LiuL, et al.Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells: A potential agent for the treatment of ocular surface defects? Transfusion, 2004; 44(12):1724–1731.
55.
LiuL, HartwigD, HarloffS, et al.Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest Ophthalmol Vis Sci, 2006; 47(6):2438–2444.
56.
FreireV, AndolloN, EtxebarriaJ, et al.In vitro effects of three blood derivatives on human corneal epithelial cells. Invest Ophthalmol Vis Sci, 2012; 53(9):5571–5578.
57.
TanidirST, YukselN, AltintasO, et al.The effect of subconjunctival platelet-rich plasma on corneal epithelial wound healing. Cornea, 2010; 29(6):664–669.
58.
López-PlandolitS, MoralesM-C, FreireV, et al.Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea, 2011; 30(12):1312–1317.
59.
López-PlandolitS, MoralesM-C, FreireV, et al.Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea, 2010; 29(8):843–848.
60.
LiJ, BallimD, RodriguezM, et al.The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem, 2014; 289(51):35633–35643.
61.
HuT, MengS, LiuC, et al.LCN2 deficiency mitigates the neuroinflammatory damage following acute glaucoma. Theranostics, 2025; 15(7):2967–2990.
62.
AiG, ShaoX, MengM, et al.Epidermal growth factor promotes proliferation and maintains multipotency of continuous cultured adipose stem cells via activating STAT signal pathway in vitro. Medicine (Baltimore), 2017; 96(30):e7607.
63.
ShibuyaM. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti-and pro-angiogenic therapies. Genes Cancer, 2011; 2(12):1097–1105.
64.
ChenF, ZhangK, WangM, et al.VEGF‐FGF signaling activates Quiescent CD63+ liver stem cells to proliferate and differentiate. Advanced Science, 2024; 11(33):2308711.
65.
BrudnoY, Ennett-ShepardAB, ChenRR, et al.Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials, 2013; 34(36):9201–9209.
66.
AndraeJ, GalliniR, BetsholtzC. Role of platelet-derived growth factors in physiology and medicine. Genes Dev, 2008; 22(10):1276–1312.
YunY-R, WonJE, JeonE, et al.Fibroblast growth factors: Biology, function, and application for tissue regeneration. J Tissue Eng, 2010; 2010:218142.
70.
CichaI, Goppelt‐StruebeM. Connective tissue growth factor: Context‐dependent functions and mechanisms of regulation. Biofactors, 2009; 35(2):200–208.
71.
SinghSK, DwivediSD, YadavK, et al.Novel biotherapeutics targeting biomolecular and cellular approaches in diabetic wound healing. Biomedicines, 2023; 11(2):613.
72.
RampinA. Faculty of Health Sciences, School of Veterinary Medicine Department of Clinical Studies, Equine unit. School of Veterinary Medicine, Aristotle University of Thessaloniki, Greece: 2023.
73.
SuvasS. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol, 2017; 199(5):1543–1552.
74.
TellecheaALA. Cellular and Molecular Mechanisms of Impaired Wound Healing in Diabetes: Understanding the Role of Substance P and Mast Cells. Universidade de Coimbra (Portugal); 2014.
75.
AndiaI, MaffulliN. Blood-Derived Products for Tissue Repair/Regeneration. MDPI; 2019.
76.
RossiL, MurrayI, ChuC, et al.Classification systems for platelet-rich plasma. Bone Joint J, 2019; 101-B(8):891–896.
77.
M Dohan EhrenfestD, BieleckiT, MishraA, et al.In search of a consensus terminology in the field of platelet concentrates for surgical use: Platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol, 2012; 13(7):1131–1137.
78.
EymardF, OrnettiP, MailletJ, GRIP (Groupe de Recherche sur les Injections de PRP, PRP Injection Research Group). et al.; Intra-articular injections of platelet-rich plasma in symptomatic knee osteoarthritis: A consensus statement from French-speaking experts. Knee Surg Sports Traumatol Arthrosc, 2021; 29(10):3195–3210.
79.
FerrariM, ZiaS, ValbonesiM, et al.A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs, 1987; 10(1):47–50.
80.
HartwigD, HerminghausP, WedelT, et al.Topical treatment of ocular surface defects: Comparison of the epitheliotrophic capacity of fresh frozen plasma and serum on corneal epithelial cells in an in vitro cell culture model. Transfus Med, 2005; 15(2):107–113.
81.
Prado ValR. Plasma rich in growth factors technology: Characterization, regulatory framework, current trends and perspectives. 2020.
82.
AnituaE, MuruzabalF, TayebbaA, et al.Autologous serum and plasma rich in growth factors in ophthalmology: Preclinical and clinical studies. Acta Ophthalmol, 2015; 93(8):e605–e614.
83.
TsubotaK, GotoE, ShimmuraS, et al.Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology, 1999; 106(10):1984–1989.
84.
EsquenaziS, HeJ, BazanHE, et al.Use of autologous serum in corneal epithelial defects post-lamellar surgery. Cornea, 2005; 24(8):992–997.
85.
SolakogluÖ, HeydeckeG, AmiriN, et al.The use of plasma rich in growth factors (PRGF) in guided tissue regeneration and guided bone regeneration. A review of histological, immunohistochemical, histomorphometrical, radiological and clinical results in humans. Ann Anat, 2020; 231:151528.
86.
FoxRI, ChanR, MichelsonJB, et al.Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum, 1984; 27(4):459–461.
87.
TsubotaK, GotoE, FujitaH, et al.Treatment of dry eye by autologous serum application in Sjögren’s syndrome. Br J Ophthalmol, 1999; 83(4):390–395.
NakamuraM, NishidaT, MishimaH, et al.Effects of antimicrobials on corneal epithelial migration. Curr Eye Res, 1993; 12(8):733–740.
90.
PengL, WuZ, SunW, et al.Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia. Invest New Drugs, 2024; 42(5):575–580.
91.
EvertsPA, KnapeJT, WeibrichG, et al.Platelet-rich plasma and platelet gel: A review. J Extra Corpor Technol, 2006; 38(2):174–187.
92.
AndiaI, MaffulliN. A contemporary view of platelet-rich plasma therapies: Moving toward refined clinical protocols and precise indications. Regen Med, 2018; 13(6):717–728.
93.
PuzzitielloRN, PatelBH, ForlenzaEM, et al.Adverse impact of corticosteroids on rotator cuff tendon health and repair: A systematic review of basic science studies. Arthrosc Sports Med Rehabil, 2020; 2(2):e161–e169.
94.
BeitzelK, AllenD, ApostolakosJ, et al.US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine. J Knee Surg, 2015; 28(1):29–34.
95.
EvertsPA, HoffmannJ, WeibrichG, et al.Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. Transfus Med, 2006; 16(5):363–368.
96.
MazzuccoL, BalboV, CattanaE, et al.Not every PRP‐gel is born equal Evaluation of growth factor availability for tissues through four PRP‐gel preparations: Fibrinet®, RegenPRP‐Kit®, Plateltex® and one manual procedure. Vox Sang, 2009; 97(2):110–118.
97.
MacsaiMS. The management of corneal trauma: Advances in the past twenty-five years. Cornea, 2000; 19(5):617–624.
98.
Rodríguez-AresMT, TouriñoR, López-ValladaresMJ, et al.Multilayer amniotic membrane transplantation in the treatment of corneal perforations. Cornea, 2004; 23(6):577–583.
99.
AlioJL, RodriguezAE, MartinezLM. Bovine pericardium membrane (tutopatch) combined with solid platelet-rich plasma for the management of perforated corneal ulcers. Cornea, 2013; 32(5):619–624.
100.
AnituaE. The use of plasma-rich growth factors (PRGF) in oral surgery. Pract Proced Aesthet Dent, 2001; 13(6):487–493; quiz 487.
101.
IntiniG. The use of platelet-rich plasma in bone reconstruction therapy. Biomaterials, 2009; 30(28):4956–4966.
102.
AnituaE, OriveG, PlaR, et al.The effects of PRGF on bone regeneration and on titanium implant osseointegration in goats: A histologic and histomorphometric study. J Biomed Mater Res A, 2009; 91(1):158–165.
103.
RoldánJC, JepsenS, SchmidtC, et al.Sinus floor augmentation with simultaneous placement of dental implants in the presence of platelet‐rich plasma or recombinant human bone morphogenetic protein‐7. Clin Oral Implants Res, 2004; 15(6):716–723.
104.
GargAK, GargeneseD, PeaceI. Using platelet-rich plasma to develop an autologous membrane for growth factor delivery in dental implant therapy. Dent Implantol Update, 2000; 11(6):41–44.
105.
SánchezM, AnituaE, AzofraJ, et al.Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: A retrospective cohort study. Clin Exp Rheumatol, 2008; 26(5):910–913.
106.
SánchezM, AnituaE, AzofraJ, et al.Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med, 2007; 35(2):245–251.
107.
ManD, PloskerH, Winland-BrownJE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg, 2001; 107(1):229–236.
108.
MazorZ, PelegM, GargAK, et al.Platelet-rich plasma for bone graft enhancement in sinus floor augmentation with simultaneous implant placement: Patient series study. Implant Dent, 2004; 13(1):65–72.
109.
VelichN, NémethZ, HrabákK, et al.Repair of bony defect with combination biomaterials. J Craniofac Surg, 2004; 15(1):11–15.
110.
SiebrechtMA, De RooijPP, ArmDM, et al.Platelet Concentrate Increases Bone Ingrowth into Porous Hydroxyapatite. SLACK Incorporated: Thorofare, NJ; 2002.
111.
LiebermanJR, DaluiskiA, EinhornTA. The role of growth factors in the repair of bone: Biology and clinical applications. Jbjs, 2002; 84(6):1032–1044.
112.
RaoufiniaR, RahimiHR, SaburiE, et al.Advances and challenges of the cell-based therapies among diabetic patients. J Transl Med, 2024; 22(1):435; doi: 10.1186/s12967-024-05226-3
113.
YoonKC, HeoH, JeongIY, et al.Therapeutic effect of umbilical cord serum eyedrops for persistent corneal epithelial defect. Korean J Ophthalmol, 2005; 19(3):174–178.
114.
YoonK-C, ChoiW, YouI-C, et al.Application of umbilical cord serum eyedrops for recurrent corneal erosions. Cornea, 2011; 30(7):744–748.
115.
OhH-J, JangJ-Y, LiZ, et al.Effects of umbilical cord serum eye drops in a mouse model of ocular chemical burn. Curr Eye Res, 2012; 37(12):1084–1090.
116.
SharmaN, GoelM, VelpandianT, et al.Evaluation of umbilical cord serum therapy in acute ocular chemical burns. Invest Ophthalmol Vis Sci, 2011; 52(2):1087–1092.
117.
YoonK-C, HeoH, ImS-K, et al.Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol, 2007; 144(1):86–92.e2.
118.
YouJ, HodgeC, HoqueM, et al.Human platelets and derived products in treating ocular surface diseases–a systematic review. Clin Ophthalmol, 2020; 14:3195–3210.
119.
WalkdenA. Amniotic membrane transplantation in ophthalmology: An updated perspective. Clin Ophthalmol, 2020; 14:2057–2072.
120.
SaburiE, AbazariMF, HassanniaH, et al.The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19. Gene, 2021; 777:145471.
121.
FotiR, ZeppieriM, FotiR, et al.Umbilical cord blood-derived products in autoimmune systemic syndromes with severe dryness: A pilot study. Medicina (Kaunas), 2024; 60(11):1764.
122.
AmablePR, CariasRBV, TeixeiraMVT, et al.Platelet-rich plasma preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors. Stem Cell Res Ther, 2013; 4(3):67.
123.
Alaoui MdarhriH, BenmessaoudR, YacoubiH, et al.Alternatives therapeutic approaches to conventional antibiotics: Advantages, limitations and potential application in medicine. Antibiotics (Basel), 2022; 11(12):1826.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
